The reiteration of a Buy rating and maintenance of a $35 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short-term impact on aTyr Pharma's stock price. The analyst's optimism is likely based on underlying fundamentals or expected future performance of the company, which could encourage investment.